₹689.85 apiece on BSE. The company's consolidated net profit stood at ₹26.58 crore for the quarter ended March 31, from ₹11.73 crore a year ago.
The company's consolidated revenue from operations increased 30% as a result of increased consumer accessibility because it now sells pharmaceuticals both online and through its physical stores all throughout the nation.
The retail division's sales, which makes up almost half of the total revenue, increased by about 29% to ₹1,241 crore due to new product launches and increased production of already-existing products.
Gross store additions of 284 stores were made in Q4 FY23, according to the company's exchange filing. With an impressive Store Level EBITDA margin of 10.3% and an overall EBITDA margin of 5%, our stores older than 12 months have continued to mature along their current trend.